Skip to main content

Published locations for FDA gives nod to tralokinumab for adults with moderate to severe AD

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA gives nod to tralokinumab for adults with moderate to severe AD

User login

  • Reset your password
  • /content/fda-gives-nod-tralokinumab-adults-moderate-severe-ad
  • /clinicianreviews/article/250288/atopic-dermatitis/fda-gives-nod-tralokinumab-adults-moderate-severe
  • /edermatologynews/article/250288/atopic-dermatitis/fda-gives-nod-tralokinumab-adults-moderate-severe
  • /familypracticenews/article/250288/atopic-dermatitis/fda-gives-nod-tralokinumab-adults-moderate
  • /internalmedicinenews/article/250288/atopic-dermatitis/fda-gives-nod-tralokinumab-adults-moderate
  • /internalmedicine/article/250288/atopic-dermatitis/fda-gives-nod-tralokinumab-adults-moderate-severe
  • /dermatology/article/250288/atopic-dermatitis/fda-gives-nod-tralokinumab-adults-moderate-severe-ad
  • /familymedicine/article/250288/atopic-dermatitis/fda-gives-nod-tralokinumab-adults-moderate-severe-ad